BIO Statement on President’s Proposed 2020 Budget
Thursday, March 14, 2019 11:01 AM

Washington, DC (March 11, 2019) – Biotechnology Innovation Organization (BIO) President and CEO Jim Greenwood issued the following statement today regarding President Trump’s FY 2020 budget proposal:

“While we are still reviewing the details of the President’s proposed budget, we applaud the President’s efforts to lower patients’ out of pocket costs for prescription drugs, and to rein in abuses and increase accountability within the 340B drug discount program."

“That said, we have serious concerns that elements of this proposal threaten to harm some of the nation’s most vulnerable patients, including seniors and low-income families. The budget would fundamentally upset the successful Medicare drug benefit that has provided American seniors with affordable prescription drug coverage while costing taxpayers less than originally expected."

Read more...
 
Emory Technology Transfer presents 13th Celebration of Technology & Innovation
Tuesday, March 12, 2019 12:00 AM

Emory University’s Office of Technology Transfer will celebrate its faculty entrepreneurs and their innovative discoveries at the 13th Annual Celebration of Technology and Innovation.

The celebration will be held Thursday, March 21, 2019 at the Emory Conference Center, Silver Bell Pavilion, 1615 Clifton Rd., Atlanta, GA 30322.

Registration begins at 4:30 p.m., and the program begins at 5 p.m., followed by a reception.

RSVP here!

For questions, contact Quentin Thomas: [email protected], 404-727-1899

Learn more here

 
Senate Moves to Stop $20 Billion Tax Increase on MedTech Industry
Thursday, March 07, 2019 11:13 AM

WASHINGTON, D.C. – Scott Whitaker, president and CEO of the Advanced Medical Technology Association (AdvaMed), issued the following statement on introduction of bipartisan legislation the Protect Medical Innovation Act  in the U.S. Senate to permanently repeal the medical device excise tax: 

“Unless Congress acts quickly, America’s medical technology companies face a $20 billion tax hike at the end of 2019 when the device excise tax returns. If not stopped, this tax will put future patient innovations and good-paying U.S. jobs at risk. 

“Today’s Senate action is the first step in ensuring continued American leadership of this vital industry. We thank the bill’s lead sponsors, Sens. Pat Toomey (R-Pa.) and Amy Klobuchar (D-Minn.), for their long-standing support of improving patient lives and medtech innovation. The broad bipartisan backing of this bill reflects members’ understanding of the negative impact on job creation, investment and patient care should this tax return, and the urgent need for repeal. 

Read more...
 
GeoVax and Leidos Expand Collaboration to Malaria Vaccines
Monday, March 04, 2019 10:24 AM

ATLANTA, GA, March 4, 2019 – GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, announced today that it has expanded its collaboration activities with Leidos, Inc. to develop malaria vaccine candidates. The work will be supported under a contract to Leidos from the United States Agency for International Development (USAID) Malaria Vaccine Development Program (MVDP). Leidos has been tasked by USAID to advance promising vaccine candidates against P. falciparum malaria and selected the GeoVax MVA-VLP platform as part of this development effort.

GeoVax’s vaccine technology is based on its live Modified Vaccinia Ankara (MVA) platform, which generates vaccine antigens, in the form of multimeric proteins or noninfectious VLPs, in the individual being vaccinated. Gene sequences of target antigens are inserted into the MVA genome which drives their expression and budding from the infected cells. In this way, vaccination strategy mimics a natural viral infection which induces two pools of proteins – virus-infected cells and released multimeric or VLP proteins.

Read more...
 
Georgia Research Alliance 'at a pivot point,' refocusing for the future
Friday, February 15, 2019 12:00 AM

By Maria Saporta  – Contributing Writer, Atlanta Business Chronicle 

Leaders behind the Georgia Research Alliance are seeking to gain traction under the administration of newly-elected Gov. Brian Kemp

The Alliance, launched during the administration of the late Gov. Zell Miller, is a well-respected organization of top business, university and government leaders dedicated to increasing the state’s technology portfolio.

At its quarterly board meeting Feb. 7, a combination of old and new faces were present. David Ratcliffe, retired CEO of Southern Co., was named board chairman – a role he had held in 2005. It also was Russell Allen’s first board meeting as president and CEO of the organization. 

“We are on the verge of taking this to the next level,” Ratcliffe said. “I think we are at a pivot point with a new administration and a new focus." 

Already Ratcliffe, Allen and Mark Sanders, who is GRA’s lobbyist and a longtime friend of the new governor, have met with Kemp, who has promised to attend future meetings. Ratcliffe said Kemp understands the success the Alliance has had over the years and appears open to exploring new opportunities to work with the organization.

Read more...
 
<< first < Prev 1 2 3 4 5 6 7 8 9 10 Next > last >>

Page 7 of 46